Exploratory analysis of time between symptom onset and enrollment.
- Leon Di Stefano (13883550)
- Elizabeth L. Ogburn (4042610)
- Malathi Ram (347523)
- Daniel O. Scharfstein (13883553)
- Tianjing Li (277569)
- Preeti Khanal (13883556)
- Sheriza N. Baksh (9525046)
- Nichol McBee (6559139)
- Joshua Gruber (11334354)
- Marianne R. Gildea (13883559)
- Megan R. Clark (13883562)
- Neil A. Goldenberg (13883565)
- Yussef Bennani (13883568)
- Samuel M. Brown (3343772)
- Whitney R. Buckel (13883571)
- Meredith E. Clement (13883574)
- Mark J. Mulligan (9413294)
- Jane A. O’Halloran (9961094)
- Adriana M. Rauseo (13883577)
- Wesley H. Self (6253940)
- Matthew W. Semler (6253931)
- Todd Seto (462814)
- Jason E. Stout (9617361)
- Robert J. Ulrich (13883580)
- Jennifer Victory (9729573)
- Barbara E. Bierer (8463141)
- Daniel F. Hanley (10043765)
- Daniel Freilich (347230)
Publication date
September 2022
DOI Publisher
Public Library of Science (PLoS)Abstract
Post-hoc exploratory analysis of subgroups based on time between symptom onset and enrollment. Subgroups are based on approximate tertiles. Shown are (A) proportional odds ratios from models fit by maximum likelihood within each subgroup, with 95% CIs; (B) the empirical risk of survival for each treatment group within each subgroup, with 95% CIs; and (C) empirical risk differences within each subgroup, with 95% CIs. HCQ/CQ indicates hydroxychloroquine or chloroquine. (PDF)</p
Add to ORKG